Clinical Trial

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-29; most recent amendment 2026-02-04.
Status change: Not Yet Recruiting → Recruiting 2026-01-12
Trial Details
NCT Number NCT07330674
Lead Sponsor Aptabio Therapeutics, Inc.
Conditions Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration
Enrollment 68 participants
Start Date 2026-02
Primary Completion 2027-11 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-06